Epigral Ltd's Q2FY25 PAT Jumps 111% to ₹ 81 Crore, Expands CPVC & Epichlorohydrin Capacity
Nov 09 2024 | a year agoEpigral Ltd, a leading integrated chemical manufacturer in India, announced its financial results for the quarter ended September 30, 2024. The company's profit after tax (PAT) for Q2FY25 surged by 111% to ₹ 81 Crore compared to ₹ 38 Crore in Q2FY24. Total revenue for the quarter rose by 32% to ₹ 632 Crore from ₹ 479 Crore in Q2FY24. Epigral's board approved the expansion of CPVC resin capacity to 1,50,000 TPA and Epichlorohydrin (ECH) capacity to 1,00,000 TPA at its Dahej facility in Gujarat. This expansion will make Epigral's CPVC resin facility the largest in the world and ECH facility the largest in India. The company is investing in Pure.rBrine™ technology for recycling and reuse of by-products, aiming for sustainability and cost rationalization. Epigral plans to double its CPVC Resin and ECH capacity, with additional capacities expected to be commissioned by H1 of FY2027. The company successfully raised ₹ 333 Crore through QIP to support its growth plans.
- Epigral's Q2FY25 PAT jumps 111% to ₹ 81 Crore
- Total revenue for Q2FY25 rose by 32% to ₹ 632 Crore
- CPVC resin capacity to be expanded to 1,50,000 TPA and ECH to 1,00,000 TPA
- Investment in Pure.rBrine™ technology for recycling and reuse of by-products
- Epigral raised ₹ 333 Crore through QIP to support growth plans